Early Detection and Prognostic Assessment of Cutaneous Melanoma Consensus on Optimal Practice and the Role of Gene Expression Profile Testing

被引:16
作者
Kashani-Sabet, Mohammed [1 ]
Leachman, Sancy A. [2 ,3 ]
Stein, Jennifer A. [4 ]
Arbiser, Jack L. [5 ]
Berry, Elizabeth G. [2 ,3 ]
Celebi, Julide T. [4 ]
Curiel-Lewandrowski, Clara [6 ]
Ferris, Laura K. [7 ,8 ]
Grant-Kels, Jane M. [9 ,10 ]
Grossman, Douglas [11 ]
Kulkarni, Rajan P. [2 ,3 ]
Marchetti, Michael A. [12 ]
Nelson, Kelly C. [13 ]
Polsky, David [4 ]
Seiverling, Elizabeth V. [14 ]
Swetter, Susan M. [15 ,16 ]
Tsao, Hensin [17 ,18 ]
Verdieck-Devlaeminck, Alexandra [2 ,3 ]
Wei, Maria L. [19 ,20 ]
Bar, Anna [2 ,3 ]
Bartlett, Edmund K. [12 ]
Bolognia, Jean L. [21 ]
Bowles, Tawnya L. [22 ]
Cha, Kelly B. [23 ]
Chu, Emily Y. [24 ]
Hartman, Rebecca I. [17 ,18 ]
Hawryluk, Elena B. [17 ,18 ]
Jampel, Risa M. [25 ]
Karapetyan, Lilit [26 ]
Kheterpal, Meenal [27 ]
Lawson, David H. [5 ]
Leming, Philip D. [28 ]
Liebman, Tracey N. [4 ]
Ming, Michael E. [24 ]
Sahni, Debjani [29 ]
Savory, Stephanie A. [30 ]
Shaikh, Saba S. [31 ]
Sober, Arthur J. [17 ,18 ]
Sondak, Vernon K. [26 ]
Spaccarelli, Natalie [32 ]
Usatine, Richard P. [33 ]
Venna, Suraj [34 ]
Kirkwood, John M. [7 ,8 ]
机构
[1] Calif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Res Inst, San Francisco, CA USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Dermatol, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Family Med, Portland, OR USA
[4] NYU Langone Hlth, Ronald O Perelman Dept Dermatol, New York, NY USA
[5] Emory Univ, Winship Canc Inst, Atlanta Vet Adm Hlth Ctr, Dept Dermatol,Sch Med, Atlanta, GA USA
[6] Univ Arizona, UA Canc Ctr Skin Canc Inst, Coll Med, Div Dermatol, Tucson, AZ USA
[7] Univ Pittsburgh, UPMC Hillman Canc Ctr, Dept Dermatol, Pittsburgh, PA USA
[8] Univ Pittsburgh, UPMC Hillman Canc Ctr, Dept Med, Pittsburgh, PA USA
[9] Univ Connecticut, Sch Med, Dept Dermatol, Farmington, CT USA
[10] Univ Florida, Dept Dermatol, Coll Med, Gainesville, FL USA
[11] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[12] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY USA
[13] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA
[14] Tufts Univ, Sch Med, Dept Dermatol, Boston, MA USA
[15] Stanford Univ, Med Ctr & Canc Inst, Dept Dermatol, Pigmented Lesion & Melanoma Program, Palo Alto, CA USA
[16] VA Palo Alto Hlth Care Syst, Dermatol Serv, Palo Alto, CA USA
[17] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA
[18] Harvard Med Sch, Boston, MA USA
[19] Univ Calif San Francisco, Dermatol Dept, San Francisco, CA USA
[20] San Francisco VA Hlth Care Syst, Dermatol Serv, San Francisco, CA USA
[21] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT USA
[22] Intermt Med Ctr, Murray, UT USA
[23] Michigan Med, Dept Dermatol, Ann Arbor, MI USA
[24] Univ Penn, Dept Dermatol, Philadelphia, PA USA
[25] Univ Maryland, Dept Dermatol, Baltimore, MD USA
[26] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[27] Duke Univ, Dept Dermatol, Durham, NC USA
[28] Cincinnati Canc Advisors, Cincinnati, OH USA
[29] Boston Med Ctr, Boston, MA USA
[30] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX USA
[31] Fox Chase Canc Ctr, Dept Hematol Oncol, Philadelphia, PA USA
[32] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[33] Univ Texas Hlth, San Antonio, TX USA
[34] Univ Virginia, Inova Fairfax Hosp, Inova Schar Canc Inst, Sch Med, Charlottesville, VA USA
关键词
RISK-FACTORS; SKIN-CANCER; METAANALYSIS; DIAGNOSIS;
D O I
10.1001/jamadermatol.2023.0127
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Importance Therapy for advanced melanoma has transformed during the past decade, but early detection and prognostic assessment of cutaneous melanoma (CM) remain paramount goals. Best practices for screening and use of pigmented lesion evaluation tools and gene expression profile (GEP) testing in CM remain to be defined.Objective To provide consensus recommendations on optimal screening practices and prebiopsy diagnostic, postbiopsy diagnostic, and prognostic assessment of CM.Evidence Review Case scenarios were interrogated using a modified Delphi consensus method. Melanoma panelists (n = 60) were invited to vote on hypothetical scenarios via an emailed survey (n = 42), which was followed by a consensus conference (n = 51) that reviewed the literature and the rationale for survey answers. Panelists participated in a follow-up survey for final recommendations on the scenarios (n = 45).Findings The panelists reached consensus (>= 70% agreement) in supporting a risk-stratified approach to melanoma screening in clinical settings and public screening events, screening personnel recommendations (self/partner, primary care provider, general dermatologist, and pigmented lesion expert), screening intervals, and acceptable appointment wait times. Participants also reached consensus that visual and dermoscopic examination are sufficient for evaluation and follow-up of melanocytic skin lesions deemed innocuous. The panelists reached consensus on interpreting reflectance confocal microscopy and some but not all results from epidermal tape stripping, but they did not reach consensus on use of certain pigmented lesion evaluation tools, such as electrical impedance spectroscopy. Regarding GEP scores, the panelists reached consensus that a low-risk prognostic GEP score should not outweigh concerning histologic features when selecting patients to undergo sentinel lymph node biopsy but did not reach consensus on imaging recommendations in the setting of a high-risk prognostic GEP score and low-risk histology and/or negative nodal status.Conclusions and Relevance For this consensus statement, panelists reached consensus on aspects of a risk-stratified approach to melanoma screening and follow-up as well as use of visual examination and dermoscopy. These findings support a practical approach to diagnosing and evaluating CM. Panelists did not reach consensus on a clearly defined role for GEP testing in clinical decision-making, citing the need for additional studies to establish the clinical use of existing GEP assays.
引用
收藏
页码:545 / 553
页数:9
相关论文
共 34 条
  • [1] Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014
    Aitken, Joanne F.
    Youlden, Danny R.
    Baade, Peter D.
    Soyer, H. Peter
    Green, Adele C.
    Smithers, B. Mark
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (08) : 1528 - 1535
  • [2] Review of diagnostic, prognostic, and predictive biomarkers in melanoma
    Ankeny, Jacob S.
    Labadie, Brian
    Luke, Jason
    Hsueh, Eddy
    Messina, Jane
    Zager, Jonathan S.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (5-6) : 487 - 493
  • [3] Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample
    Begg, CB
    Orlow, I
    Hummer, AJ
    Armstrong, BK
    Kricker, A
    Marrett, LD
    Millikan, RC
    Gruber, SB
    Anton-Culver, H
    Zanetti, R
    Gallagher, RP
    Dwyer, T
    Rebbeck, TR
    Mitra, N
    Busam, K
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (20): : 1507 - 1515
  • [4] Bradford PT, 2010, ARCH DERMATOL, V146, P265, DOI 10.1001/archdermatol.2010.2
  • [5] Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant
    Caini, Saverio
    Gandini, Sara
    Sera, Francesco
    Raimondi, Sara
    Fargnoli, Maria Concetta
    Boniol, Mathieu
    Armstrong, Bruce K.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (17) : 3054 - 3063
  • [6] Concordance Analysis of the 23-Gene Expression Signature (myPath Melanoma) With Fluorescence In Situ Hybridization Assay and Single Nucleotide Polymorphism Array in the Analysis of Challenging Melanocytic Lesions: Results From an Academic Medical Center
    Castillo, Stephanie A.
    Pham, Anh K.
    Dagrosa, Alicia T.
    Yan, Shaofeng
    Barton, Dorothea T.
    Lefferts, Joel A.
    Linos, Konstantinos
    [J]. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2020, 42 (12) : 939 - 947
  • [7] Skin Cancer and Immunosuppression
    Collins, Lindsey
    Quinn, Andrew
    Stasko, Thomas
    [J]. DERMATOLOGIC CLINICS, 2019, 37 (01) : 83 - +
  • [8] The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
    Elder, David E.
    Bastian, Boris C.
    Cree, Ian A.
    Massi, Daniela
    Scolyer, Richard A.
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2020, 144 (04) : 500 - 522
  • [9] Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study
    Elmore, Joann G.
    Barnhill, Raymond L.
    Elder, David E.
    Longton, Gary M.
    Pepe, Margaret S.
    Reisch, Lisa M.
    Carney, Patricia A.
    Titus, Linda J.
    Nelson, Heidi D.
    Onega, Tracy
    Tosteson, Anna N. A.
    Weinstock, Martin A.
    Knezevich, Stevan R.
    Piepkorn, Michael W.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [10] Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy
    Ferris, Laura K.
    Jansen, Burkhard
    Ho, Jonhan
    Busam, Klaus J.
    Gross, Kenneth
    Hansen, Doyle D.
    Alsobrook, John P., II
    Yao, Zuxu
    Peck, Gary L.
    Gerami, Pedram
    [J]. JAMA DERMATOLOGY, 2017, 153 (07) : 675 - 680